TOKUSHIMA, Japan–(BUSINESS WIRE)–Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.
The following is the current status of the interim analysis of a Phase III study of DFP-10917 monotherapy in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US.
As there are a long term surviving patients in the 150 patients enrolled in this study, we intend to continue to follow up these patients without any data cut-off for the time being to determine the final overall survival (OS) results of the study.
We ask for understanding that under a randomized and controlled study, we are unable to identify at this stage whether these surviving patients are in the DFP-10917 group or the control group (NCT03926624).
We look forward to showing the results when the data is ready to disclose.
Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.
Contacts
Inquires
Dr. Yasundo Yamasaki
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/
ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…
Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…
QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…
SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…
DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…
Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…